<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02808442</url>
  </required_header>
  <id_info>
    <org_study_id>UCART19_02 (CL1-68587-001)</org_study_id>
    <secondary_id>2015-004293-15</secondary_id>
    <nct_id>NCT02808442</nct_id>
  </id_info>
  <brief_title>Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia</brief_title>
  <acronym>PALL</acronym>
  <official_title>A Phase 1, Open Label, Non-comparative Study to Evaluate the Safety and the Ability of UCART19 to Induce Molecular Remission in Paediatric Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Servier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at evaluating the safety and ability of UCART19 to induce molecular remission
      in pediatric patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic
      leukemia (B-ALL) ahead of planned allogeneic hematopoietic stem cell transplantation
      (allo-HSCT).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Severity of Adverse Events</measure>
    <time_frame>From inclusion to Day 84 post UCART19 infusion or until the initiation of allo-HSCT conditioning regimen</time_frame>
    <description>Adverse events assessed according to NCI-CTCAE v4.03 criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and Severity of Adverse Events</measure>
    <time_frame>From Day 85 or the initiation of allo-HSCT conditioning regimen to Month 12 post allo-HSCT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular Remission Rate</measure>
    <time_frame>At Day 28 post UCART19 infusion</time_frame>
    <description>Proportion of patients in whom a molecular Complete Remission (CR) or a Complete Remission with incomplete blood recovery (CRi) is observed (i.e. a CR or CRi combined to a Minimal residual disease &lt;10-4).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Refractory B-cell Acute Lymphoblastic Leukemia</condition>
  <condition>Relapsed B-cell Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>UCART19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>UCART19</intervention_name>
    <arm_group_label>UCART19</arm_group_label>
    <other_name>S68587</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with relapsed or refractory CD19-positive B-acute lymphoblastic leukaemia
             (B-ALL)

               1. who have exhausted available treatment options

               2. eligible for allo-HSCT with suitable donor available

          -  Estimated life expectancy ≥ 12 weeks

          -  Considered medically fit for allo-HSCT

          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt; 2

        Exclusion Criteria:

          -  Burkitt leukemia

          -  CD19-negative B-cell leukemia

          -  Uncontrolled Central Nervous System (CNS) leukemia

          -  Active acute or chronic Graft-versus-Host Disease (GvHD) requiring therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Waseem Qasim, MRCP, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCL, Great Ormond Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Institut de Recherches Internationales Servier</last_name>
    <phone>+33 1 55 72 43 66</phone>
    <email>clinicaltrials@servier.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Het Kinderziekenhuis Prinses Elisabeth - UZG</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert-Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCL Great Ormond Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.servier.com</url>
    <description>Find Results on Servier Clinical Trial Data</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).
They can ask all interventional clinical studies:
submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://clinicaltrials.servier.com</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://clinicaltrials.servier.com</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>http://clinicaltrials.servier.com</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>http://clinicaltrials.servier.com</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>http://clinicaltrials.servier.com</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Study-level clinical trial data</doc_type>
      <doc_url>http://clinicaltrials.servier.com</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

